Status | Study |
Not yet recruiting |
Study Name: Study of Bortezomib (BTZ) Treatment on Mantle Cell Lymphoma (MCL) in Chinese Participants Condition: Lymphoma, Mantle-Cell Date: 2017-02-10 |
Recruiting |
Study Name: A Study of Bendamustine and Rituximab Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated Mantle Cell Lymphoma Condition: Lymphoma, Mantle Cell Date: 2016-11-21 Interventions: Drug: Acalabrutinib in combination with bendamustine and rituximab |
Recruiting |
Study Name: Trial of Bortezomib, Cytarabine, and Dexamethasone in Mantle Cell Lymphoma Condition: Mantle Cell Lymphoma Date: 2016-07-19 Interventions: Drug: Bortezomib, Cytarabine, Dexamethasone, Pegteograstim |
Terminated |
Study Name: Phase IIa Study of Copanlisib in Relapsed or Refractory Mantle Cell Lymphoma (MCL) Condition: Lymphoma, Mantle-Cell Date: 2015-05-23 Interventions: Drug: Copanlisib (BAY80-6946) Starting dose 60 mg (dose reduction due to toxicities to 45 mg allowed). A |
Completed |
Study Name: Observational Study of Lenalidomide in Subjects With Mantle Cell Lymphoma Who Failed Ibrutinib Treatment Condition: Lymphoma, Mantle-Cell Date: 2015-01-14 |
Completed |
Study Name: Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib in Participants With Relapsed or Refractory Mantle Cell Lymphoma Condition: Lymphoma, Mantle-cell Date: 2014-06-19 Interventions: Drug: Ibrutinib Participants will receive ibrutinib capsules 560 milligram (mg) orally, once daily on a |
Active, not recruiting |
Study Name: Rituximab Maintenance Therapy in Aggressive CD20 (Cluster of Differentiation Antigen 20) Positive Lymphoma and Mantle Cell Lymphoma Condition: CD20+ Aggressive Lymphoma, Mantle Cell Lymphoma Date: 2013-08-23 Interventions: Drug: rituximab |
Active, not recruiting |
Study Name: Phase II Study of Age‐Adjusted Rituximab, Bendamustine, Cytarabine as Induction Therapy in Older Patients With Mantle Cell Lymphoma Condition: Mantle Cell Lymphoma Date: 2012-06-26 Interventions: Drug: Rituximab, Bendamustine, Cytarabine. 6 cycles of 28 days with Rituximab, Bendamustine and Cytarabi |
Active, not recruiting |
Study Name: Bortezomib (VELCADE), Cladribine and Rituximab (VCR) in Mantle Cell Lymphoma (PSHCI 10-011) Condition: Mantle Cell Lymphoma Date: 2011-08-16 Interventions: Drug: Rituximab 375 mg/m2 on d |
Active, not recruiting |
Study Name: Lenalidomide Plus Rituxan for Untreated Mantle Cell Lymphoma Condition: Mantle Cell Lymphoma Date: 2011-03-24 Interventions: Drug: lenalidomide |